Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention
| Autor: | Laura Zanotti, Alberto Zaniboni, Elisabetta Zaina, Chiara Abeni, Ester Oneda, Sara Bighè |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Side effect Peripheral neuropathy Paclitaxel medicine.medical_treatment 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ovarian cancer Internal medicine medicine Chemotherapy Taxane Chemotherapy-induced peripheral neuropathy prevention business.industry Hilotherapy Minireviews medicine.disease Carboplatin Regimen 030104 developmental biology chemistry 030220 oncology & carcinogenesis business |
| Zdroj: | World Journal of Clinical Oncology |
| ISSN: | 2218-4333 |
| Popis: | Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that occurs in 20% of ovarian cancer patients treated with the combination of carboplatin/paclitaxel (CP). This toxicity is directly correlated with the dose of paclitaxel administered. Several studies have investigated whether different formulations of taxane can induce this side effect at a lower rate, but, unfortunately, no significant improvement was obtained. CIPN can be disabling in the daily lives of patients and can cause dose reduction or early termination of the treatment. Neuropathy can last for months and even years after its onset. Moreover, patients responsive to CP treatment are candidates for a reintroduction of the same drugs when disease relapse occurs, and residual neuropathy can affect the continuation of treatment. There are no approved drugs that mitigate or prevent the onset of CIPN. In this review, we summarize the evidence regarding the incidence of CIPN with different taxane formulations, regimen schedules and prevention systems. In particular, the Hilotherm® Chemo care device is a regional cooling system that lowers the temperature of the hands and feet to reduce the flow of chemotherapy into the capillaries. We used hilotherapy during chemotherapy infusion to prevent the onset of CIPN. Updated data from 44 ovarian cancer patients treated with 6 cycle of CP show that hilotherapy was well tolerated; only two patients (4.5%) stopped hilotherapy because of cold intolerance, and only one patient (2.2%) experienced grade ≥ 2 CIPN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|